糖尿病性神経因性ぼうこうに対するウラピジルの効果と評価法

• 宮下 雄博

  三菱水島病院内科

• 青山 雅

  倉敷生活習慣病センター

• 姫井 孟

  倉敷生活習慣病センター

書誌事項

タイトル別名

• Effect of Urapidil on Diabetic Neurogenic Bladder
• トウニョウビョウセイ シンケイインセイ ボウコウ ニ タイスル ウラピジル ノ コウカ ト ヒョウカホウ

抄録

Urapidil was administered orally at 30mg/day for 1 month to 22 patients (17 men and 5 women) with diabetes and bladder dysfunction.After confirming the absence of adverse reactions, the dose was increased to 60mg/day for another 5 months.Urine flow was assessed with a uroflowmeter at the end of administration. Patients were assessed for symptoms using the International Prostate Symptom Score (IPSS) and the QOL score (an index of satisfaction).Uroflowmetry showed that maximum urine flow improved from 12.3±6.2 to 15.5±10.6 (ml/s), and that mean urine flow improved from 5.2±2.6 to 7.5±4.6 (ml/s), although neither change was statistically significant.IPSS and QOL scores decreased significantly, however, from 20.1±9.2 to 10.0±7.8 and 4.8±1.0 to 2.8±1.4.Efficacy, determined from Guidelines for Clinical Studies on Urinary Dysfunction, was 62.8%.Efficacy in patients with a pretreatment single voided urine volume of less than 200ml increased to 81.8%.Urapidil may thus be useful in treating diabetic neurogenic bladder, although it is important to select appropriate methods for evaluating response.

収録刊行物

• 糖尿病

  糖尿病 47 (9), 715-722, 2004

  一般社団法人 日本糖尿病学会

キーワード

• diabetic autonomic neuropathy

詳細情報

• CRID: 1390001204904781568
• NII論文ID: 10014047191
• NII書誌ID: AN00166576
• DOI: 10.11213/tonyobyo1958.47.715
• ISSN: 1881588X
• ISSN: 0021437X
• NDL書誌ID: 025098137
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025098137
• Web Site: https://search.jamas.or.jp/link/ui/2005040463
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • NDL
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可